OncBioMune Pharmaceuticals, Inc | Business Contracts

Offer Letter between the Company and Faith Zaslavsky, dated December 5, 2022 (Filed With SEC on December 9, 2022)

Form of Security Agreement (Filed With SEC on December 1, 2022)

Placement Agency Agreement by and between the Company and Joseph Gunnar & Co (Filed With SEC on December 1, 2022)

Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk effective January 1, 2021 (Filed With SEC on January 13, 2022)

Form of Securities Purchase Agreement (Filed With SEC on December 1, 2022)

Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Exchanged Debentures) (Filed With SEC on December 1, 2022)

Form of Common Stock Purchase Warrant (Filed With SEC on December 1, 2022)

Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Filed With SEC on December 1, 2022)

Form of Demand Note (Filed With SEC on September 16, 2022)

Form of Securities Purchase Agreement for April 2022 (Filed With SEC on May 23, 2022)

Form of Common Stock Purchase Warrant for April 2022 (Filed With SEC on May 23, 2022)

Form of Convertible Promissory Note for April 2022 (Filed With SEC on May 23, 2022)

Form of Common Stock Purchase Warrant 2 (Filed With SEC on February 3, 2022)

Engagement Letter, by and between Carter, Terry & Company and Theralink Technologies, Inc., dated December 15, 2021, as amended (Filed With SEC on February 3, 2022)

Form of Securities Purchase Agreement (Filed With SEC on February 3, 2022)

Securities Purchase Agreement, dated November 1, 2021 (Filed With SEC on November 5, 2021)

Form of Common Stock Purchase Warrant, issued November 1, 2021 (Filed With SEC on November 5, 2021)

Form of Convertible Promissory Note, dated November 1, 2021 (Filed With SEC on November 5, 2021)

Employment Agreement, dated June 5, 2020 by and between Jeffrey Busch and OncBioMune Pharmaceuticals, Inc (Filed With SEC on September 27, 2021)

Employment Agreement, dated June 5, 2020 by and between Dr. Michael Ruxin and OncBioMune Pharmaceuticals, Inc (Filed With SEC on September 27, 2021)

Securities Purchase Agreement, dated July 30, 2021 (Filed With SEC on August 6, 2021)

Common Stock Purchase Warrant, issued July 30, 2021 (Filed With SEC on August 6, 2021)

Security Agreement, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Securities Purchase Agreement, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Common Stock Purchase Warrant, issued May 12, 2021 (Filed With SEC on May 19, 2021)

Convertible Secured Promissory Note, dated May 12, 2021 (Filed With SEC on May 19, 2021)

Form of Registration Rights Agreement (Filed With SEC on April 20, 2021)

Form of Subscription Agreement (Filed With SEC on April 20, 2021)

Securities Purchase Agreement, dated September 16, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investor (Filed With SEC on September 22, 2020)

Consulting Agreement between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020 (Filed With SEC on June 11, 2020)

Separation Agreement and General Release of Claims between OncBioMune Pharmaceuticals, Inc. and Andrew Kucharchuk dated June 5, 2020 (Filed With SEC on June 11, 2020)

Securities Purchase Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. Cavalry Fund I LP and Lincoln Park Capital Fund, LLC (Filed With SEC on June 11, 2020)

Exchange Agreement, dated June 5, 2020, by and between OncBioMune Pharmaceuticals, Inc. and Jonathan F. Head, Ph.D (Filed With SEC on June 11, 2020)

Exchange Agreement, dated June 5, 2020, by and among OncBioMune Pharmaceuticals, Inc. and the Investors named therein (Filed With SEC on June 11, 2020)

Exchange Warrant, dated June 5, 2020 (Filed With SEC on June 11, 2020)

Form of Warrant (Filed With SEC on June 11, 2020)

Asset Purchase Agreement, dated May 12, 2020, between OncBioMune Pharmaceuticals, Inc. and Avant Diagnostics, Inc (Filed With SEC on May 13, 2020)

Description of Capital Stock (Filed With SEC on March 25, 2020)

Securities Purchase Agreement dated September 25, 2019 (Filed With SEC on November 19, 2019)

Warrant dated September 25, 2019 (Filed With SEC on November 19, 2019)

Note dated September 25, 2019 (Filed With SEC on November 19, 2019)

Securities Purchase Agreement (Filed With SEC on August 6, 2019)

Form of Warrant (Filed With SEC on August 6, 2019)

Form of Note (Filed With SEC on August 6, 2019)

Form of Note (Filed With SEC on July 18, 2019)

Form of Securities Purchase Agreement (Filed With SEC on July 18, 2019)

Form of Warrant (Filed With SEC on July 18, 2019)

Form of Securities Purchase Agreement (Filed With SEC on May 2, 2019)

Form of Warrant (Filed With SEC on May 2, 2019)

Form of Note (Filed With SEC on May 2, 2019)

Common Stock Purchase Warrant issued March 25, 2019 to Cavalry Fund I LP (Filed With SEC on April 1, 2019)

Securities Purchase Agreement between OncBioMune Pharmaceuticals, Inc. and Cavalry Fund I LP, dated March 25, 2019 (Filed With SEC on April 1, 2019)

Senior Convertible Note issued March 25, 2019 to Cavalry Fund I LP (Filed With SEC on April 1, 2019)

Employment Agreement effective as of December 26, 2018 between OncBioMune Pharmaceuticals, Inc. and Brian Barnett, MD (Filed With SEC on April 1, 2019)

Shareholders Agreement among OncBioMune Pharmaceuticals, Inc., Jonathan F. Head, Ph.D., Andrew A. Kucharchuk, Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March... (Filed With SEC on February 21, 2019)

Irrevocable Trust Agreement Number F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. as beneficiaries and Banco... (Filed With SEC on February 21, 2019)

Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March... (Filed With SEC on February 21, 2019)

Convertible Redeemable Note, dated as of January 18, 2019 (Filed With SEC on February 4, 2019)

Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and Cerberus Finance Group Ltd (Filed With SEC on February 4, 2019)

Securities Purchase Agreement, dated as of January 18, 2019, by and between OncBioMune Pharmaceuticals, Inc. and LG Capital Funding LLC (Filed With SEC on January 29, 2019)

Convertible Redeemable Note, dated as of January 18, 2019 (Filed With SEC on January 29, 2019)

OncBioMune Pharmaceuticals, Inc (62)